Achieve Life Sciences, Inc. (ACHV)

Achieve Life Sciences reported a net loss of $54.6 million for the full year 2025, leading to a stock price decrease due to investor concerns. The FDA accepted the NDA for cytisinicline for adult smoking cessation with a PDUFA target date of June 20, 2026. Achieve Life Sciences presented data at SRNT demonstrating successful cessation and announced a publication linking cytisinicline's receptor selectivity to low nausea rates. The company completed the ORCA-OL long-term exposure trial and closed a $45 million public offering to advance cytisinicline development. Citizens initiated coverage of Achieve Life Sciences with a Market Outperform recommendation.

Achieve Life Sciences' stock performance shows seasonality, with January being the strongest month and September the weakest. The reliability of this seasonal pattern has been inconsistent across different market conditions. Demand for its future product is more likely to be driven by public health initiatives, regulatory approvals, and healthcare provider recommendations rather than typical seasonal consumer patterns.

Achieve Life Sciences, Inc. is a late-stage clinical specialty pharmaceutical company focused on addressing smoking and nicotine addiction. The company is developing and commercializing cytisinicline, a plant-based alkaloid that interacts with nicotine receptors to reduce withdrawal symptoms. Achieve Life Sciences is advancing cytisinicline for smoking cessation and e-cigarette/vaping cessation, having completed a Phase 2 study for vaping cessation and received FDA Breakthrough and Fast Track Designation, along with a Commissioner's National Priority Voucher.

Achieve Life Sciences, Inc. operates in Canada, the United States, and the United Kingdom. The company's headquarters are located in Bothell, Washington, with an additional office in Vancouver, British Columbia, Canada.

Achieve Life Sciences' brand reputation is tied to its commitment to addressing nicotine dependence through cytisinicline. The company is viewed as focused on providing evidence-based therapy for smoking cessation. Positive developments such as FDA acceptance of the New Drug Application and Breakthrough and Fast Track Designations contribute positively to its standing. Analyst consensus rates Achieve Life Sciences with a "Moderate Buy," suggesting a positive outlook.

Achieve Life Sciences, Inc. has a mixed ownership structure including institutional, insider, and retail investors. As of March 30, 2026, institutional shareholders hold approximately 43.66% of the stock, insiders hold 19.56%, and retail investors hold 36.78%. Dialectic Capital Management LP is the largest individual shareholder.